EZH2 and breast cancer: The heterogeneity of the different breast cancer subtypes with respect to overall survival, and the possibility that tumours of different subtypes may derive from different cells of origin, suggest that the expression levels of EZH2 and BMI1 in breast tumours reflect a pre-existing expression pattern in different cell types within the mammary gland.